Clinical trial NCT02211508: Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301
Official title: A Double-Blinded, Randomized, Sham-Controlled, Pivotal Study of the NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Fibromyalgia
Keywords: fibromyalgia
pain
stimulation
Lead sponsor: Cerephex Corporation
Sponsor class: INDUSTRY
First posted: 2014-08-07
Enrollment: 236
Sex: ALL
Minimum age (years): 22
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test the safety and efficacy of a noninvasive cortical electrostimulation therapy known as "Reduced Impedance Noninvasive Cortical Electrostimulation" (RINCE) in the treatment of pain associated with fibromyalgia. Patients who meet the 2010 American College of Rheumatology criteria for fibromyalgia will receive up to 24 RINCE treatments delivered by a medical device called "NeuroPoint". Approximately 200 fibromyalgia patients will be randomized into one of two study groups. One of these groups will receive sham treatment, meaning they will receive no treatment at all, while the other group will receive active RINCE treatment. The study's primary outcome measure will be the difference between active and sham treatment groups in the mean change from baseline in patients' weekly worst pain scores. The study's hypothesis is that there will be a difference between treatment groups in primary outcome measure.


Eligibility criteria: Inclusion Criteria:

* Patient is male or female, 22 to 65 years of age, inclusive.
* Patient has a diagnosis of primary fibromyalgia as defined by the 2010 American College of Rheumatology Preliminary Diagnostic Criteria for fibromyalgia.
* If female, is either not of childbearing potential or is willing to utilize specified practices throughout the study to prevent becoming pregnant.
* Patient is willing and able to refrain or withdraw from the following therapies for the duration of the study: duloxetine, milnacipran, pregabalin, gabapentin, naltrexone, sodium oxybate, and opiates.
* Qualified patients with mild or moderate depression must be clinically stable, without risk of suicidal ideation or behavior, and the dose of allowed anti-depressants should have been stable for at least three months prior to the Baseline clinic visit.
* Patient is willing and able to comply with all protocol-specified requirements.
* Patient is capable of reading and understanding English and has provided written informed consent to participate.

Exclusion Criteria:

* The patient suffers from one or more of clinically significant psychiatric condition that could interfere with the patient's well-being or ability to comply with the protocol.
* Patient has a Beck Depression Inventory-II total score greater than 25 at either the Screening visit or Baseline clinic visit.
* The patient is at increased risk of suicide.
* Patient is unable, unwilling or not advised to refrain from or discontinue prohibited medications or treatments.
* Patient has a diagnosis of, or is being treated for, systemic lupus erythematosus, inflammatory arthritis, or other documented systemic autoimmune disorder, Parkinson's disease, multiple sclerosis, or cancer (other than basal or squamous cell skin cancer).
* Patient has any other chronic pain condition that, in the Investigator's or Sponsor's opinion, could interfere with the patient's assessment of his/her fibromyalgia status.
* Patient has a history of severe, refractory or uncontrolled migraine headaches, seizure disorder or clinically significant cognitive dysfunction.
* Patient is pregnant or planning to become pregnant within the next 6 months.
* Patient has a body mass index greater than 40 at the Screening visit.
* Patient has a history of cranial electrical stimulation or transcutaneous magnetic stimulation within 2 years of screening, or electroconvulsive therapy within 5 years of screening.
* Patient has a metal implant at or above the level of the 7th cervical vertebra, a cardiac pacemaker or defibrillator, or vagus nerve stimulator.
* Any recent surgery or anticipated need for surgery that might confound results or interfere with patient's ability to comply with the protocol.
* Myocardial infarction during the 12 months prior to screening, uncontrolled hypertension, active cardiac disease, clinically significant cardiac rhythm or conduction abnormality, or anticipation of bypass or other cardiac surgery within the next 12 months.
* Current systemic infection (e.g., HIV, hepatitis B or C; Lyme disease).
* Patient is using opiates on a regular or frequent basis.
* Pending or current litigation or disability claim (including Workman's Compensation).
* History of significant alcohol and/or drug abuse or dependency within preceding 5 years, or a positive result on the screening (or subsequent) drug screen indicating use of an illicit substance.
* Patient has participated in an investigational study of a therapeutic treatment within 90 days prior to Screening visit or is currently participating in another clinical trial.

Primary outcomes:
measure: Change from baseline in patients' 24-hour recall worst pain intensity
timeFrame: Assessed at 12 weeks
Secondary outcomes:
measure: Patient self-reported Global Impression of Change
timeFrame: Assessed at 12 weeks
measure: Proportion of patients in the treatment and sham groups whose average daily worst pain intensity decreased by at least 50%
timeFrame: Assessed at 12 weeks
measure: Change from baseline in Revised Fibromyalgia Impact Questionnaire
timeFrame: Assessed at 12 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Achieve Clinical Research, LLC
state: Alabama
city: Phoenix
country: United States
facility: Premier Research
state: Arizona
city: Napa
country: United States
facility: Neurovations
state: California
city: Sacramento
country: United States
facility: Superior Research LLC
state: California
city: San Diego
country: United States
facility: Artemis Institute for Clinical Research
state: California
city: Deland
country: United States
facility: Avail Clinical Research
state: Florida
city: Orlando
country: United States
facility: Compass Research LLC
state: Florida
city: Chicago
country: United States
facility: Chicago Research Center
state: Illinois
city: Ann Arbor
country: United States
facility: Michigan Head Pain & Neurological Institute
state: Michigan
city: New York
country: United States
facility: Fieve Clinical Research
state: New York
city: Williamsville
country: United States
facility: Upstate Clinical Research Associates
state: New York
city: Cincinnati
country: United States
facility: University of Cincinnati College of Medicine
state: Ohio
city: Medford
country: United States
facility: Sunstone Medical Research
state: Oregon
city: Warwick
country: United States
facility: Omega Medical Research
state: Rhode Island
city: Salt Lake City
country: United States
facility: Fatigue Consultation Clinic
state: Utah
city: Seattle
country: United States
facility: Swedish Clinical Research
state: Washington
Study officials:
affiliation: Cerephex Corporation
name: R. Michael Gendreau, MD PhD
role: STUDY_DIRECTOR
References:
citation: Hargrove JB, Bennett RM, Simons DG, Smith SJ, Nagpal S, Deering DE. A randomized placebo-controlled study of noninvasive cortical electrostimulation in the treatment of fibromyalgia patients. Pain Med. 2012 Jan;13(1):115-24. doi: 10.1111/j.1526-4637.2011.01292.x.
citation: Hargrove JB, Bennett RM, Clauw DJ. Long-term outcomes in fibromyalgia patients treated with noninvasive cortical electrostimulation. Arch Phys Med Rehabil. 2012 Oct;93(10):1868-71. doi: 10.1016/j.apmr.2012.04.006. Epub 2012 Apr 21.